Cited by

• Early mortality during rifampicin-resistant TB treatment.

  Mohr-Holland E, Daniels J, Reuter A, Rodriguez CA, Mitnick C, Kock Y, Cox V, Furin J, Cox H. Mohr-Holland E, et al. Int J Tuberc Lung Dis. 2022 Feb 1;26(2):150-157. doi: 10.5588/ijtld.21.0494. Int J Tuberc Lung Dis. 2022. PMID: 35086627 Free PMC article.
• Linezolid in the Starter Combination for Multidrug-Resistant Tuberculosis: Time to Move on to Group Four?

  Grard S, Catho G, Valour F, Bouaziz A, Perpoint T, Braun E, Biron F, Miailhes P, Ferry T, Chidiac C, Souquet PJ, Couraud S, Lina G, Goutelle S, Veziris N, Dumitrescu O, Ader F. Grard S, et al. Open Forum Infect Dis. 2015 Dec 22;2(4):ofv175. doi: 10.1093/ofid/ofv175. eCollection 2015 Dec. Open Forum Infect Dis. 2015. PMID: 26719846 Free PMC article.
• DOT or SAT for Rifampicin-resistant tuberculosis? A non-randomized comparison in a high HIV-prevalence setting.

  Mohr E, Daniels J, Beko B, Isaakidis P, Cox V, Steele SJ, Muller O, Snyman L, De Azevedo V, Shroufi A, Trivino Duran L, Hughes J. Mohr E, et al. PLoS One. 2017 May 18;12(5):e0178054. doi: 10.1371/journal.pone.0178054. eCollection 2017. PLoS One. 2017. PMID: 28542441 Free PMC article. Clinical Trial.
• Priority-Setting for Novel Drug Regimens to Treat Tuberculosis: An Epidemiologic Model.

  Kendall EA, Shrestha S, Cohen T, Nuermberger E, Dooley KE, Gonzalez-Angulo L, Churchyard GJ, Nahid P, Rich ML, Bansbach C, Forissier T, Lienhardt C, Dowdy DW. Kendall EA, et al. PLoS Med. 2017 Jan 3;14(1):e1002202. doi: 10.1371/journal.pmed.1002202. eCollection 2017 Jan. PLoS Med. 2017. PMID: 28045934 Free PMC article.
• Management of drug-resistant tuberculosis in special sub-populations including those with HIV co-infection, pregnancy, diabetes, organ-specific dysfunction, and in the critically ill.

  Esmail A, Sabur NF, Okpechi I, Dheda K. Esmail A, et al. J Thorac Dis. 2018 May;10(5):3102-3118. doi: 10.21037/jtd.2018.05.11. J Thorac Dis. 2018. PMID: 29997980 Free PMC article. Review.